Huberman Lab

Snapshot · Huberman Lab

Accelerate Learning & Increase Cognitive Capacity | Dr. Tommy Wood

Explore episode Jul 20, 2026

Where this was said

Shingles Vaccine & Dementia Risk; Tool: Avoid Illness for Cognitive Health

At 2:16:40 · chapter starts 2:09:47

Huberman raises the shingles vaccine dementia question as controversial but important. Wood explains the natural experiment design: in each country, on a single date, a large cohort became eligible for the shingles vaccine while those born one day earlier did not. The two groups should otherwise be near-identical. Across Wales, Australia, and Canada, the result was the same: eligible individuals (and confirmed recipients where data were available) had significantly lower subsequent dementia rates. The newer Shingrix vaccine outperformed the older live-attenuated Zostavax in a US comparison study. The mechanism isn't fully resolved — reducing shingles (varicella-zoster) outbreaks alone doesn't explain the magnitude of the benefit, so Wood and others hypothesize additional immunomodulatory effects that may also suppress herpes simplex virus, another candidate neurotropic virus linked to Alzheimer's pathology. The female-skewed benefit in some studies supports an immune mechanism. Wood then broadens the point: the Adult Changes in Thought study and Rush Memory and Aging Project both show that cognitive decline occurs in stepwise drops after major illnesses — with hospitalizations causing the largest acute drops. Minimizing severe illness, including through vaccination, is therefore a genuine dementia prevention strategy.

Similar snapshots